source
- BeOne Medicines receives accelerated FDA approval for sonrotoclax in mantle cell lymphomaBeOne Medicines announced that the U.S. Food and Drug Administration granted accelerated approval to its BCL2 inhibitor sonrotoclax for treatment of mantle cell lymphoma. The approval is based on…
- AVB-001 Cell Therapy Demonstrates Safety and Immune Activation in Platinum-Resistant Ovarian CancerAVB-001, an encapsulated interleukin-2 cell therapy, was evaluated in patients with platinum-resistant high-grade serous ovarian carcinoma. The study reported that the treatment was well tolerated.…